Reuters logo
OncoMed's lung cancer drug fails mid-stage study
April 17, 2017 / 12:27 PM / 8 months ago

OncoMed's lung cancer drug fails mid-stage study

April 17 (Reuters) - OncoMed Pharmaceuticals Inc said on Monday its experimental drug failed a mid-stage study for the treatment of lung cancer.

The trial was testing the combination of Oncomed’s tarextumab and chemotherapy, compared with chemotherapy and a placebo. The main goal was to slow the progression of the disease.

Last week, the company said it would discontinue a trial testing its experimental drug, demcizumab, as an initial treatment for advanced pancreatic cancer. (Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Anil D‘Silva)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below